Article
Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase.
Science (New York, N.Y.) - 27 Sept 1991
St Clair M H, Martin J L, Tudor-Williams G, Bach M C, Vavro C L, King D M, Kellam P, Kemp S D, Larder B A
Abstract excerpt
Serial human immunodeficiency virus type-1 (HIV-1) isolates were obtained from five individuals with acquired immunodeficiency syndrome (AIDS) who changed therapy to 2',3'-dideoxyinosine (ddI) after at least 12 months of treatment with 3'-azido-3'-deoxythymidine (zidovudine, AZT). The in vitro sensitivity to ddI decreased during the 12 months following ddI initiation, whereas AZT sensitivity increased. Analysis...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.